While a prognostically favorable impact of HER4 has been primarily observed in HER2-positive and triple-negative BC, an unfavorable effect has been associated with estrogen receptor (ESR)-positive (i.e., luminal) BC [2]. This evidence concerns the gene ERBB4 and breast cancer.